Lung inflammation and immunity: report from the 12th ERS Lung Science Conference.

Eur Respir Rev

Inserm, U1152, LabEx Inflamex, Paris, France. Université Paris Diderot, Sorbonne Paris Cité, Paris, France. Service de Pneumologie, APHP, Hôpital Bichat, DHU Fire, Paris, France. Laboratory of Immunoregulation and Mucosal Immunology, Inflammation Research Center-VIB, Ghent University, Ghent, Belgium.

Published: September 2014

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487325PMC
http://dx.doi.org/10.1183/09059180.00004714DOI Listing

Publication Analysis

Top Keywords

lung inflammation
4
inflammation immunity
4
immunity report
4
report 12th
4
12th ers
4
ers lung
4
lung science
4
science conference
4
lung
2
immunity
1

Similar Publications

COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time.

Rheumatol Int

December 2024

Department of General Practice N2, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.

We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020-2023) and compares the same with the pre-pandemic period (2016-2019). We assume that SARS-CoV-2 triggers ARD.

View Article and Find Full Text PDF

Predictors of high-flow nasal cannula (HFNC) failure in severe community-acquired pneumonia or COVID-19.

Intern Emerg Med

December 2024

Department of Respiratory Medicine and Allergology, University Hospital, Goethe University, Frankfurt, Germany.

The aim was to identify predictors for early identification of HFNC failure risk in patients with severe community-acquired (CAP) pneumonia or COVID-19. Data from adult critically ill patients admitted with CAP or COVID-19 and the need for ventilatory support were retrospectively analysed. HFNC failure was defined as the need for invasive ventilation or death before intubation.

View Article and Find Full Text PDF

This study investigated the incidence of new-onset cardiovascular disorders up to 3.5 years post SARS-CoV-2 infection for 56,400 individuals with COVID-19 and 1,093,904 contemporary controls without COVID-19 in the Montefiore Health System (03/11/2020 to 07/01/2023). Outcomes were new incidence of major adverse cardiovascular event (MACE), arrhythmias, inflammatory heart disease, thrombosis, cerebrovascular disorders, ischemic heart disease and other cardiac disorders between 30 days and (up to) 3.

View Article and Find Full Text PDF

Background: Despite evidence from experimental studies linking some petroleum hydrocarbons to markers of immune suppression, limited epidemiologic research exists on this topic.

Objective: The aim of this cross-sectional study was to examine associations of oil spill related chemicals (benzene, toluene, ethylbenzene, xylene, and n-hexane (BTEX-H)) and total hydrocarbons (THC) with immune-related illnesses as indicators of potential immune suppression.

Methods: Subjects comprised 8601 Deepwater Horizon (DWH) oil spill clean-up and response workers who participated in a home visit (1-3 years after the DWH spill) in the Gulf Long-term Follow-up (GuLF) Study.

View Article and Find Full Text PDF

The aim of this study was to evaluate how COVID-19 affected acute stroke care and outcome in patients with acute ischemic or hemorrhagic stroke. We performed a retrospective analysis on patients who were admitted with acute ischemic (AIS) or hemorrhagic (ICH) stroke from September 2020 to May 2021 with and without COVID-19. We recorded demographic and clinical data, imaging parameters, functional outcome and mortality at one year.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!